Real-life Experience with 4 years of Golimumab Persistence in Ulcerative Colitis Patients

Overview

Journal Sci Rep

Specialty Science

Date 2020 Oct 21

PMID 33082359

Citations 9

Authors

Marisa Iborra

Natalia Garcia-Morales

Saoia Rubio

Federico Bertoletti

Marta Calvo

Carlos Taxonera

Marta Maia Bosca-Watts

Monica Sierra

Noemi Mancenido

Belen Beltran

Oscar Nantes Castillejo

Esther Garcia-Planella

Isabel Vera

Cristina Alba

David Marti-Aguado

Maria Pilar Ballester

Noelia Cano-Sanz

Ramon Pajares-Villarroya

Elena Cerrillo

Antonio Canada

Pilar Nos

Affiliations

Soon will be listed here.

Abstract

Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence of golimumab, as well as factors associated with longer persistence, in patients with ulcerative colitis in real life. Observational multicentre study including adult patients with ulcerative colitis treated with golimumab and with at least twelve months of follow-up. We included 190 patients, 105 (55.26%) naive to anti-TNF, with mean disease duration of 9.32 ± 8.09 years. Probability of persistence was 63%, 46%, 39% and 27% at 1, 2, 3 and 4 years, respectively. Persistence was lower in patients with primary failure to previous anti-TNF. Eighty-two (43.16%) patients needed dose intensification during follow-up, with a mean time until intensification of 8.03 ± 8.64 months. Dose intensification and lower disease duration predicted higher persistence with golimumab (p = 0.037 and p = 0.008, respectively). During a follow-up of 17.25 ± 15.83 months, 32 (16.5%) patients needed hospitalisation and 11 (6%) underwent colectomy. No unexpected adverse events were reported. Golimumab has demonstrated good persistence and safety profile for long treatment in ulcerative colitis patients.

Citing Articles

Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study.

Hirayama D, Motoya S, Ashida T, Ando K, Fujiya M, Ito T Inflamm Intest Dis. 2023; 8(3):115-127.

PMID: 38098492 PMC: 10718581. DOI: 10.1159/000533871.

Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon.

Park S Crohns Colitis 360. 2023; 5(3):otad046.

PMID: 37691730 PMC: 10492443. DOI: 10.1093/crocol/otad046.

Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies.

Weinstein C, Meehan A, Govoni M, Lin J, Reinisch W Crohns Colitis 360. 2023; 5(3):otad044.

PMID: 37691729 PMC: 10492447. DOI: 10.1093/crocol/otad044.

The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review.

Awan H, Fatima U, Eaw R, Knox N, Alrubaiy L Cureus. 2023; 15(4):e37609.

PMID: 37069838 PMC: 10105519. DOI: 10.7759/cureus.37609.

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan.

Nakamura S, Asano T, Tanaka Y, Sugimoto K, Yoshigoe S, Suzuki Y Inflamm Intest Dis. 2023; 7(3-4):128-138.

PMID: 37064538 PMC: 10090977. DOI: 10.1159/000528185.

References

Satsangi J, Silverberg M, Vermeire S, Colombel J . The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55(6):749-53. PMC: 1856208. DOI: 10.1136/gut.2005.082909. View

Fine S, Papamichael K, Cheifetz A . Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2020; 15(12):656-665. PMC: 6935028. View

Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso F, Cappello M . A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Dig Liver Dis. 2018; 50(12):1292-1298. DOI: 10.1016/j.dld.2018.06.008. View

Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017; 11(6):649-670. DOI: 10.1093/ecco-jcc/jjx008. View

Bossuyt P, Baert F, DHeygere F, Nakad A, Reenaers C, Fontaine F . Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflamm Bowel Dis. 2018; 25(1):156-162. DOI: 10.1093/ibd/izy219. View

Adedokun O, Gunn G, Leu J, Gargano C, Xu Z, Sandborn W . Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019; 25(9):1532-1540. DOI: 10.1093/ibd/izz003. View

Philip G, Cornillie F, Adedokun J, Melsheimer R, Rutgeerts P, Colombel J . Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. J Crohns Colitis. 2019; 13(10):1257-1264. DOI: 10.1093/ecco-jcc/jjz052. View

Ha C, Mathur J, Kornbluth A . Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015; 9(4):497-505. DOI: 10.1586/17474124.2015.983079. View

Taxonera C, Iborra M, Bosca-Watts M, Rubio S, Nantes O, Higuera R . Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Curr Med Res Opin. 2019; 35(7):1297-1304. DOI: 10.1080/03007995.2019.1579557. View

10.

Iannone F, Santo L, Anelli M, Bucci R, Semeraro A, Quarta L . Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2017; 47(1):108-114. DOI: 10.1016/j.semarthrit.2017.01.008. View

11.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

12.

Bossa F, Biscaglia G, Valvano M, Costantino G, Lauria A, Clemente R . Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci. 2019; 65(6):1767-1776. DOI: 10.1007/s10620-019-05904-z. View

13.

Cross R . Which patients with inflammatory bowel disease should receive combination therapy?. Expert Rev Gastroenterol Hepatol. 2015; 9(6):715-7. DOI: 10.1586/17474124.2015.1039989. View

14.

Hernandez M, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C . Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int. 2018; 39(3):509-515. DOI: 10.1007/s00296-018-4177-z. View

15.

Sarkar S, Seshadri D . Conducting record review studies in clinical practice. J Clin Diagn Res. 2014; 8(9):JG01-4. PMC: 4225918. DOI: 10.7860/JCDR/2014/8301.4806. View

16.

Lopetuso L, Gerardi V, Papa V, Scaldaferri F, Rapaccini G, Gasbarrini A . Can We Predict the Efficacy of Anti-TNF-α Agents?. Int J Mol Sci. 2017; 18(9). PMC: 5618622. DOI: 10.3390/ijms18091973. View

17.

Vande Casteele N, Khanna R . Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res. 2017; 34(8):1556-1563. DOI: 10.1007/s11095-017-2150-2. View

18.

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):96-109.e1. DOI: 10.1053/j.gastro.2013.06.010. View

19.

Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L . Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2018; 51(3):327-334. DOI: 10.1016/j.dld.2018.11.002. View

20.

Rotar Z, Tomsic M, Praprotnik S . The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide.... Clin Rheumatol. 2018; 38(2):297-305. DOI: 10.1007/s10067-018-4324-7. View